We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AML floisand
Previous Study | Return to List | Next Study

DC Vaccination for Post-remission Therapy in AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02405338
Recruitment Status : Completed
First Posted : April 1, 2015
Last Update Posted : July 7, 2020
Information provided by (Responsible Party):
Medigene AG

Brief Summary:

This is a multi-centre, open label, prospective, non-randomized phase I/II trial in 20 patients including a safety-run in phase I part comprising 6 patients.

Trial subjects will receive repeated immunotherapies with autologous Dendritic Cells (DCs), presenting two leukemia-associated antigens.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Biological: WT1/PRAME vaccination Phase 1 Phase 2

Detailed Description:

20 patients with AML who are in remission (ELN criteria by Döhner et al 2017) receive WT1/PRAME autologous DC vaccine by intradermal injection once per week during the first 4 weeks and 1 per month thereafter for 23 consecutive months.

Primary objective is to assess the safety and tolerability of the DC vaccine in the aforementioned population and the feasibility.

Secondary objectives include evaluation of clinical response and exploratory immune monitoring assessments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens
Actual Study Start Date : March 2015
Actual Primary Completion Date : November 2019
Actual Study Completion Date : November 2019

Arm Intervention/treatment
Experimental: WT1/PRAME vaccination Biological: WT1/PRAME vaccination

Primary Outcome Measures :
  1. Percentage of patients in whom treatment with the scheduled number of immunotherapies is feasible [ Time Frame: 2 years ]
  2. Percentage of grade I/II, grade III/IV and grade ≥III toxicities in patients having received at least 1 immunotherapy [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 2 years ]
  2. Relapse/Progression free survival [ Time Frame: 2 years ]
  3. Time to progression (TTP). [ Time Frame: 2 years ]
  4. Control of minimal residual disease (MRD) [ Time Frame: 2 years ]
  5. ECOG performance status [ Time Frame: 2 years ]
  6. Cellular immune responses to applied antigens [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Acute Myeloid Leukemia (AML)
  • Age 18 - 75 years
  • Morphologic remission (CR) with or without hematological recovery (CRi) following induction chemotherapy
  • WT1 with or without PRAME positivity by qPCR
  • Negative pregnancy test in women of childbearing potential (within 7 days before the first vaccination). Women of childbearing potential and sexually active male participants must use reliable methods of contraception during the whole treatment period and 3 months after the last trial drug dose
  • Negative HIV 1 and 2 test, Hepatitis B and C test and negative Syphilis test at screening
  • Informed consent signed prior to any trial related activities

Exclusion Criteria:

  • Patients suitable for allogeneic stem cell transplantation
  • AML M3 (acute promyelocytic leukemia)
  • Patients not in complete remission (CR or CRi), bone marrow blast count ≥ 5 %
  • Active immunodeficiency syndromes
  • Concurrent active second malignancy other than non-melanoma skin cancers
  • Clinically relevant autoimmune disease
  • Prior immunotherapy
  • Severe organ dysfunction precluding the apheresis procedure:
  • Creatinine > 200 mmol/l
  • Bilirubin, ALAT and ASAT > 3 x upper normal limit
  • Respiratory insufficiency with pO2 < 60 mmHg
  • Clinically relevant coronary heart disease of ventricular arrhythmia, congestive heart failure > grade II NYHA
  • Recent cerebral hemorrhage
  • Known allergies to substances used in the generation of DCs
  • Other severe acute or chronic medical psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or the administration of the investigational product
  • Use of corticosteroids
  • Active CMV infection (Antibody-positivity due to previous, now inactive infection is accepted)
  • Inability to comply with the trial protocol
  • Participation in other clinical trials that, according to the investigator's discretion, may interfere with this trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02405338

Layout table for location information
Oslo University Hospital, Rikshospitalet
Oslo, Norway, 0424
Sponsors and Collaborators
Medigene AG
Layout table for investigator information
Principal Investigator: Yngvar Fløisand Oslo University Hospital, Rikshospitalet Department of Hematology
Layout table for additonal information
Responsible Party: Medigene AG
ClinicalTrials.gov Identifier: NCT02405338    
Other Study ID Numbers: CD-FDC-001
First Posted: April 1, 2015    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: July 2019
Keywords provided by Medigene AG:
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type